Medical technology company Sirigen Group Ltd has completed two financing rounds totalling £3.83 million led by a syndicate of new investors including IQ Capital, NESTA, the National Endowment for Science, Technology and the Arts and YFM Private Equity. Existing investors, Seraphim Capital and Oxford Capital Partners followed on.
The money will be used to commercialise Sirigen’s High Sensitivity Fluorescence (HSF) technology, which is designed to boost the performance of in vitro diagnostic tools. The company says HSF provides the basis for improved analysis and management of diseases including HIV and leukaemia, and is expected to improve clinical outcomes for many patients as a result. The technology can also be used in clinical research.
HSF detection simplifies sample processing and instrumentation requirements in both immunodiagnostic and nucleic acid based applications, and allows high volume screening in theradiagnostics and other personal care applications.
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
